SAGE Therapeutics — CNS Disorders

Sage Therapeutics
"Sage Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders."

SAGE-217
"SAGE-217 is a novel, selective, next generation GABAA positive allosteric modulator that shares similar pharmacology properties to brexanolone. We are initially developing SAGE-217 as a once-daily, oral therapy for treatment of various CNS disorders."

Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

• Expedited SAGE-217 development plan to support potential NDA submission for MDD and PPD
• Previously completed placebo-controlled study in MDD considered as pivotal; initiation of one additional Phase 3 pivotal trial anticipated in 2H of 2018.
• Ongoing study in PPD designated as pivotal; results expected in 4Q 2018.
• If successfully developed, SAGE-217 has the potential to be the first durable, rapid-acting, oral, short-course treatment for MDD and PPD

Further Exploitation of GABAA and NMDA Receptors
"We are exploring additional potential products in a variety of CNS disorders based on modulation of both the GABAA and NMDA receptors. In addition to our products focused on SE, other GABAA mediated CNS disorders upon which we believe our approach can have a material impact include Rett syndrome, Dravet syndrome, fragile X syndrome, anxiety, depression, sleep disorders, mania, tremor, tinnitus and post-traumatic stress disorder."

"Enhancing GABA pharmacologically (benzodiazepines) or physiologically (more Typer II or somatosensory inputs) could quiet tinnitus" - Dr. Robert Aaron Levine

Dr. Robert Aaron Levine's Tinnitus...

 

hey i posted that video earlier

 

@Contrast I also posted what @Autumnly posted, but I'm glad that she reposted it because I can't post more as I recently bought shares 3 weeks ago. With that I think that the share price is too high. I'm going to sell tomorrow.

 

SAGE-217 is the new xanax

 

There’s also brexanolon (formerly known as SAGE-547) which is administered as an intravenous therapy designed to correct imbalances in GABA signaling within the brain. It’s an acute interventional treatment for postpartum depression and already through phase 3. The FDA has accepted the filing of a New Drug Application and granted Priority Review status.

But I have no idea which drug (brexanolon or SAGE-217) would be more effective in treating tinnitus (if they can actually treat tinnitus).

 

Does anybody know if this drug being developed by SAGE working on correcting the GABA has helped tinnitus?

 

@Paulmanlike

The company won't comment on that. Maybe they will with other design therapy.

All drugs of this nature will probably require IV injection as this one with approval in link below for 60 hours. Will healthcare consider it cost effective to treat tinnitus with IV injection long term. This may be the reason for SAGE holding back on a direct GABA treatment for tinnitus. It's important as an awareness cause to have hospitals and doctors realize that tinnitus is a severe condition.


https://www.fiercebiotech.com/biotech/fda-panel-backs-sage-s-postpartum-depression-drug-17-1-vote

 

SAGE has got a Buy rating, I saw you previously bought stock in the company, did you sell it in the end or you holding on?

 

Sage Therapeutics to Provide Update on Key 2019 Initiatives at J.P. Morgan Healthcare Conference

• Launch of ZULRESSO (brexanolone) in the U.S., if approved, will follow the anticipated scheduling of brexanolone by the Drug Enforcement Administration (DEA), and is projected for June 2019.
• Statistically significant results achieved in Phase 3 trial of SAGE-217 in postpartum depression
• First patient dosed in second pivotal trial of SAGE-217 in major depressive disorder

 

SAGE is in completion of raising 575 million to add to the hundreds of millions that they already have in the bank.

In the last year they have been putting together what appears to be a solid patent library of compounds for tinnitus.

Neuroactive steroids, compositions, and uses thereof

Three of their many patents

(1) Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I): and pharmaceutically acceptable thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, traumatic brain injury, vascular diseases, substance withdrawal syndromes, and tinnitus.

19-nor neuroactive steroids and methods of use thereof

(2) Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (1): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, pain, traumatic brain injury, vascular diseases, withdrawal syndromes, tinnitus, . Brain Cognition Diseases Mood Disorder Personality Disorder Sleep Disorder Tinnitus Traumatic Brain Injury Vascular Diseases

(3) Neuroactive steroids, compositions, and uses thereof
Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus

Behind '547, Sage is developing a spate of CNS therapies that modulate the brain's GABAA and NMDA receptors, including preclinical treatments for depression, essential tremor, tinnitus and pain.

Last year I posted a form where one could just type 'please develop a tinnitus drug as soon as possible'.

Their depression drug is a non benzo with hardly any taper needed.
In my opinion they could raise another 2 to 3 billion from Wall Street with no problems.

Awareness - Go to the money that has research and the patents. Someone that can save us and not some treatment that might help a small percentage.

 

So this might come out in 3 months?
Is anyone going to try it?
I imagine you have to travel to USA to try it?

 

Your reference is to a depression non benzo non taper neuro depression drug. This is a first in class and most have thought that it was impossible. I have no idea if it will help with tinnitus and the company won't discuss this as it's not part of label.

They are doing neuro research on tinnitus and pain, but in their conference call they are at present focusing on other neuro disease and conditions. Can they do the impossible with a tinnitus drug even though it may take years to develop? They have important patents that may slow others down with tinnitus research.

I think that this is our only hope as tinnitus is a neuro brain disease. I just think that most to all other treatments will just make money for those with these procedures and for those within these communication areas.

There's a few with physical tinnitus of more than one year that do see their tinnitus fade due to physical treatments. A few more will receive lowering, but healthcare often doesn't investigate and use research study. Studies have recently come out and said that certain tests are needed for physical tinnitus which include a FONAR stand up MRI for the neck and 3D cone beam scan for jaw.

 

@Greg Sacramento can you please provide links to SAGE Therapeutics where they say they are doing research into tinnitus drug treatments?

 

This is the only real hope of a breakthrough that I personally have.
The idea of gizmos relaying electric currents to already damaged nerve cells sounds very dodgy to me; it could have the potential for further damage I reckon.
It all looks like a ‘hit and miss - trial and error’ set up, rather than genuine science.
Drugs can effectively treat headaches, migraines, Parkinson’s, anxiety, and tons of other conditions.
Before Greg brought this up I hadn’t seen any reference to it?
We just have to hope.....x

 

Besides with tinnitus patent registrations it mentioned in the other SAGE thread.
They are doing some serious tinnitus patent collecting and they have a strong BOD presence in the tinnitus space.
Jeff Jonas
https://www.sagerx.com/about-us/our-team/

With this, I would think that a Phase I will be coming in a few years if not sooner.
I personally will not make an investment because EPS earnings per share is expected to drop going into 2020. From about -2.00 to over -10.00. That's would be a big drop in earnings per share.

 

@Greg Sacramento

It seems they have a bunch of patents looking for a nail to hit with a hammer.

I contacted SAGE regarding their patents and asked if they had any plans to initiate any trials for tinnitus.

As expected they said they cannot discuss this unfortunately, and gave me links to their clinical trials and pipeline.

 

Any update to this?

 

• SAGE-217 is still in Phase 3
• Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSO™ (brexanolone) Injection
  • was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019
    
  • first and only treatment specifically approved for postpartum depression (PPD)
    
  • The Company expects to launch ZULRESSO in late June as planned.
  • ZULRESSO is administered via continuous intravenous (IV) infusion for 2.5 days under the supervision of healthcare providers in sites of care certified under the ZULRESSO Risk Evaluation and Mitigation Strategy (REMS) program. The one-time infusion offers the potential for rapid resolution of depressive symptoms of PPD.
• Still don't know if these drugs could help with tinnitus